ClinicalTrials.gg
Active, not recruitingNCT07211633Updated Oct 23, 2026

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)

A Phase 3 interventional study of Ublituximab and Ublituximab in Relapsing Multiple Sclerosis, sponsored by TG Therapeutics, Inc.. Active, not recruiting at 48 sites in 9 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by TG Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing ublituximab in Multiple Sclerosis — 5 open to participants now, 7 under way, 4 of them phase 3. ublituximab · Multiple Sclerosis.

Planned enrollment
5th of 10
360 · median 355
Started
2025
with 1 other
Phase 3
5 of 10
1 open now
Registered
6th of 10
by date
Lead sponsor
8 of 10
TG Therapeutics, Inc.

Among the 10 studies testing ublituximab in Multiple Sclerosis, this one is the 5th largest by planned enrollment, is one of 2 that started in 2025, is one of 5 in phase 3, and was the 6th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

5 of the 10 studies testing ublituximab in Multiple Sclerosis are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ublituximab

ublituximab: first FDA approval 2022 (BRIUMVI), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing ublituximab in Multiple Sclerosis, or all of them as a file.
02

Study summary

The purpose of this study is to assess the pharmacokinetics of ublituximab when administered subcutaneously (SC) compared to intravenous (IV) administration in participants with RMS.

Read the detailed description

This is a Phase 3, open label, parallel-group, multicenter study in participants with RMS.

03

Conditions studied

  • Relapsing Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of RMS (2017 Revised McDonald criteria).
  2. Expanded Disability Status Scale (EDSS) score ≤ 5.5 at screening.
  3. Neurologically stable for > 30 days prior to Screening and Day 1.
  4. Female participants of must consent to use a highly effective method of from consent and for 6 months after the last dose of ublituximab.

Exclusion criteria

Exclusion Criteria:

  1. Primary-progressive Multiple Sclerosis (PPMS) or inactive Secondary Progressive Multiple Sclerosis (SPMS).
  2. Active chronic disease of the immune system other than MS or immunodeficiency syndrome.
  3. Participants with significantly impaired bone marrow function or significant leukopenia or thrombocytopenia.
  4. Participants who previously received anti-CD20 therapy at any time; any approved therapy to treat MS within 5 half-lives of the medication prior to screening.

Note: Other Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
360 participants (estimated)

Study arms

  • Active comparator
    Ublituximab IV

    Approved dosage.

    Biological: Ublituximab

  • Experimental
    Ublituximab SC Regimen 1

    New regimen.

    Biological: Ublituximab

  • Experimental
    Ublituximab SC Regimen 2

    New regimen.

    Biological: Ublituximab

Interventions

  • BiologicalUblituximab

    Administered as an IV infusion.

    Also known as: TG-1101

  • BiologicalUblituximab

    Administered as an SC injection.

    Also known as: TG-1101

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Week 0 to Week 24 (AUC0-W24) of Ublituximab

    Time frame: Up to Week 24

Secondary outcomes

  1. Minimum Plasma Concentration (Cmin) of Ublituximab

    Time frame: Up to Week 24

  2. Average Concentration at Steady State (Cavg,ss) of Ublituximab

    Time frame: Up to Week 120

  3. Maximum Plasma Concentration (Cmax) of Ublituximab

    Time frame: Up to Week 120

  4. Time to Maximum Plasma Concentration (Tmax) of Ublituximab

    Time frame: Up to Week 120

  5. Last Observed Concentration (Clast) of Ublituximab

    Time frame: Up to Week 120

  6. Area Under the Curve From Week 0 to Week 120 (AUC0-120) of Ublituximab

    Time frame: Up to Week 120

  7. Concentration From Time 0 to Time of Last Concentration (AUClast) of Ublituximab

    Time frame: Up to Week 120

  8. Time of Last Concentration (Tlast) of Ublituximab

    Time frame: Up to Week 120

  9. Participants B Cell Counts

    Time frame: Up to Week 120

  10. Incidence of Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to Week 120

  11. Total Number of Gadolinium (Gd) enhancing T1 Lesions Per Magnetic Resonance Imaging (MRI) Scan

    Time frame: Up to Week 96

  12. Total Number of New or Enlarging T2 lesions Per MRI Scan

    Time frame: Up to Week 96

07

Study locations

48 sites
  • TG Therapeutics Investigational Trial Site
    Banja Luka, 78000, Bosnia and Herzegovina
  • TG Therapeutics Investigational Trial Site
    Bihać, 77000, Bosnia and Herzegovina
  • TG Therapeutics Investigational Trial Site
    Mostar, 71000, Bosnia and Herzegovina
  • TG Therapeutics Investigational Trial Site
    Saravejo, 71000, Bosnia and Herzegovina
  • TG Therapeutics Investigational Trial Site
    Tulza, 75000, Bosnia and Herzegovina
  • TG Therapeutics Investigational Trial Site
    Pleven, 5800, Bulgaria
  • TG Therapeutics Investigational Trial Site
    Plovdiv, 4000, Bulgaria
  • TG Therapeutics Investigational Trial Site
    Sofia, 1000, Bulgaria
  • TG Therapeutics Investigational Trial Site
    Sofia, 1113, Bulgaria
  • TG Therapeutics Investigational Trial Site
    Veliko Tarnovo, 5000, Bulgaria
  • TG Therapeutics Investigational Trial Site
    Varaždin, 42000, Croatia
  • TG Therapeutics Investigational Trial Site
    Zagreb, 10000, Croatia
  • TG Therapeutics Investigational Trial Site
    Brno, 65691, Czechia
  • TG Therapeutics Investigational Trial Site
    Hradec Králové, 50005, Czechia
  • TG Therapeutics Investigational Trial Site
    Jihlava, 58601, Czechia
  • TG Therapeutics Investigational Trial Site
    Ostrava, 70300, Czechia
  • TG Therapeutics Investigational Trial Site
    Pardubice, 53002, Czechia
  • TG Therapeutics Investigational Trial Site
    Zlín, 76275, Czechia
  • TG Therapeutics Investigational Trial Site
    Tbilisi, 0112, Georgia
  • TG Therapeutics Investigational Trial Site
    Tbilisi, 0114, Georgia
  • TG Therapeutics Investigational Trial Site
    Tbilisi, 0159, Georgia
  • TG Therapeutics Investigational Trial Site
    Tbilisi, 0172, Georgia
  • TG Therapeutics Investigational Trial Site
    Tbilisi, 0178, Georgia
  • TG Therapeutics Investigational Trial Site
    Tbilisi, 0179, Georgia
  • TG Therapeutics Investigational Trial Site
    Tbilisi, 0180, Georgia
  • TG Therapeutics Investigational Trial Site
    Tbilisi, 3700, Georgia
  • TG Therapeutics Investigational Trial Site
    Budapest, H-1033, Hungary
  • TG Therapeutics Investigational Trial Site
    Budapest, H-1044, Hungary
  • TG Therapeutics Investigational Trial Site
    Budapest, H-1145, Hungary
  • TG Therapeutics Investigational Trial Site
    Kaposvár, H-7400, Hungary
  • TG Therapeutics Investigational Trial Site
    Kistarsca, H-2143, Hungary
  • TG Therapeutics Investigational Trial Site
    Pécs, H-7623, Hungary
  • TG Therapeutics Investigational Trial Site
    Shtip, 7240, North Macedonia
  • TG Therapeutics Investigational Trial Site
    Skopje, 1000, North Macedonia
  • TG Therapeutics Investigational Trial Site
    Kragujevac, 34 000, Serbia
  • TG Therapeutics Investigational Trial Site
    Niš, 18000, Serbia
  • TG Therapeutics Investigational Trial Site
    Cherkasy, 14029, Ukraine
  • TG Therapeutics Investigational Trial Site
    Ivano-Frankivsk, 76000, Ukraine
  • TG Therapeutics Investigational Trial Site
    Ivano-Frankivsk, 76018, Ukraine
  • TG Therapeutics Investigational Trial Site
    Ivano-Frankivsk, 76493, Ukraine
  • TG Therapeutics Investigational Trial Site
    Kyiv, 03037, Ukraine
  • TG Therapeutics Investigational Trial Site
    Kyiv, 03115, Ukraine
  • TG Therapeutics Investigational Trial Site
    Lviv, 79000, Ukraine
  • TG Therapeutics Investigational Trial Site
    Lviv, 79010, Ukraine
  • TG Therapeutics Investigational Trial Site
    Lviv, 79029, Ukraine
  • TG Therapeutics Investigational Trial Site
    Ternopil, 46027, Ukraine
  • TG Therapeutics Investigational Trial Site
    Vinnytsia, 21002, Ukraine
  • TG Therapeutics Investigational Trial Site
    Vinnytsia, 21009, Ukraine
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Oct 2026, 15 months after the start.

Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's planned 15 months is below that.

Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2025
First posted
Oct 8, 2025
StartActual
Jul 9, 2025
Primary completionEst.
Oct 31, 2026
CompletionEst.
Dec 31, 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07211633
Responsible party
Sponsor
First posted
Oct 8, 2025
Start date
Jul 9, 2025
Primary completion
Oct 31, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ublituximab

Start the discussion